News BenevolentAI names pharma vet Jörg Möller as its new CEO BenevolentAI’s search for a new chief executive has concluded with the appointment of industry bigwig Dr Jörg Möller to the role, four months after Joanna Shields stepped
Views & Analysis LEO Pharma’s new R&D lead on driving agility in drug develop... After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face